Tevogen Bio Holdings (TVGN) Accounts Payables (2021 - 2026)

Tevogen Bio Holdings has reported Accounts Payables for 6 years, with the latest figure at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 18.57% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (down 18.57% YoY), and the FY2025 full-year result was $3.3 million, down 35.77% from the prior year.
• Accounts Payables for Q1 2026 stood at $3.8 million, up from $3.3 million in the prior quarter.
• The five-year high for Accounts Payables was $6.7 million in Q2 2024, with the low at $128999.0 in Q1 2022.
• Historically, Accounts Payables has averaged $2.9 million across 5 years, with a median of $3.3 million in 2025.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 1524.29% — and 2025, when it tumbled 43.27%.
• Tevogen Bio Holdings' Accounts Payables stood at $210454.0 in 2022, then jumped by 1524.29% to $3.4 million in 2023, then jumped by 52.13% to $5.2 million in 2024, then plunged by 35.77% to $3.3 million in 2025, then grew by 13.73% to $3.8 million in 2026.
• The last three Accounts Payables figures came in at $3.8 million (Q1 2026), $3.3 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.